Blurbs

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Dynavax (DVAX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allogene Therapeutics (ALLOResearch Report) and Dynavax (DVAXResearch Report) with bullish sentiments.

Allogene Therapeutics (ALLO)

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Allogene Therapeutics, with a price target of $23.00. The company’s shares closed last Monday at $10.88.

According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.5% and a 28.8% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

Currently, the analyst consensus on Allogene Therapeutics is a Moderate Buy with an average price target of $26.75, representing a 153.6% upside. In a report issued on September 22, B.Riley Financial also maintained a Buy rating on the stock with a $18.00 price target.

See the top stocks recommended by analysts >>

Dynavax (DVAX)

Dynavax received a Buy rating and a $22.00 price target from JMP Securities analyst Roy Buchanan today. The company’s shares closed last Monday at $9.93.

According to TipRanks.com, Buchanan is ranked 0 out of 5 stars with an average return of -27.7% and a 20.9% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Arbutus Biopharma, and Hookipa Pharma.

Currently, the analyst consensus on Dynavax is a Strong Buy with an average price target of $24.67, representing a 140.9% upside. In a report issued on September 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $28.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALLO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos